Premium
Type IV Phosphodiesterase Inhibitor Suppresses Insulin‐Dependent Myocardial Glucose Uptake
Author(s) -
Imahashi Kenichi,
Yoshioka Jun,
Yamakita Tsuyoshi,
Yamano Suzuyo,
Kusuoka Hideo,
Nishimura Tsunehiko
Publication year - 2001
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1046/j.1440-1681.2001.03440.x
Subject(s) - rolipram , medicine , phosphodiesterase , endocrinology , insulin , phosphodiesterase inhibitor , glucose uptake , chemistry , enzyme , biochemistry
SUMMARY 1. Phosphodiesterase (PDE) IV has been localized at cardiomyocytes and the coronary vasculature and modulates cAMP, but the effect of PDE IV on myocardial glucose uptake has not been demonstrated. 2. Glucose uptake in rat isolated hearts treated with the PDE IV inhibitor rolipram was measured by [ 31 P] nuclear magnetic resonance spectroscopy. 3. Under non‐stimulating conditions, glucose uptake was not significantly different between control and rolipram (1 μ mol/L)‐treated rat hearts, whereas enhanced uptake in insulin‐stimulated conditions was significantly attenuated by rolipram. 4. Phosphodiesterase IV inhibitor negatively affects insulin‐dependent myocardial glucose uptake.